2. Search Result
Search Result
Results for "

Radiolabeling

" in MedChemExpress (MCE) Product Catalog:

112

Inhibitors & Agonists

1

Fluorescent Dye

8

Biochemical Assay Reagents

23

Peptides

4

Inhibitory Antibodies

3

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100675
    JTE-013
    Maximum Cited Publications
    10 Publications Verification

    		 LPL Receptor Apoptosis Cancer
    JTE-013 is a potent and specific S1P2 (Sphingosine-1-Phosphate 2; EDG-5) antagonist. JTE-013 inhibits the specific binding of radiolabeled S1P to human and rat S1P2 with IC50s of 17 nM and 22 nM, respectively .
    JTE-013
  • HY-P99020
    Fresolimumab
    1 Publications Verification

    GC1008

    		 TGF-beta/Smad Metabolic Disease Inflammation/Immunology Cancer
    Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
    Fresolimumab
  • HY-W087028
    NOTA-NHS ester

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents CXCR Cancer
    NOTA-NHS ester is a chelating agent. NOTA-NHS ester can be coupled with T140 (HY-P4810) to produce NOTA-T140. NOTA-T140 can be radiolabeled with Al[ 18F]. The uptake of Al[ 18F]NOTA-T140 in tumors is correlated with the expression level of CXCR4. Al[ 18F]NOTA-T140 can be used in tumor PET imaging studies. NOTA-NHS ester can be used for fluorescent labeling .
    NOTA-NHS ester
  • HY-120947
    AV-105

    		Drug Intermediate Neurological Disease
    AV-105 is a Florbetapir ( 18F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize 18F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .
    AV-105
  • HY-W614269
    DOTA-GA(tBu)4

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-GA(tBu)4 stabilizes the attachment of radiometals to ligands. DOTA-GA(tBu)4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA(tBu)4 targets HER2>-expressing breast and gastrointestinal cancer .
    DOTA-GA(tBu)4
  • HY-134797
    p-SCN-Bn-deferoxamine
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    P-SCN-Bn-deferoxamine is a bifunctional chelating agent that can link radioactive metal nuclides (such as Zr-89) and biological targeting molecules (such as antibodies). P-SCN-Bn-deferoxamine can be used for the research of immune PET imaging .
    p-SCN-Bn-deferoxamine
  • HY-W087027
    Maleimide-NOTA

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Integrin Cancer
    Maleimide-NOTA is a chelate. Maleimide-NOTA can be site-specifically coupled to the hPD-L1 nanobody bearing the Cys-tag. Maleimide-NOTA can specifically conjugate to A20FMDV2 (HY-P1654). The [ 68Ga]Ac-CG6 formed by the conjugation of 68Ga radiolabeled Maleimide-NOTA with A20FMDV2 can be used for PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma .
    Maleimide-NOTA
  • HY-P10761
    DPI-4452

    		Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase Cancer
    DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DPI-4452
  • HY-175023A
    OncoACP3 TFA

    		Phosphatase Cancer
    OncoACP3 TFA is a small-molecule ligand of prostatic acid phosphatase (ACP3) with an IC50 of 0.30 nM. OncoACP3 TFA has a modular structure that supports flexible payload delivery. After radiolabeling with Lu-177 it selectively accumulates in ACP3-expressing tumors with a long retention time, enabling targeted radiation delivery. OncoACP3 TFA is applicable to research related to prostate cancer .
    OncoACP3 TFA
  • HY-W250574
    NOTA-bis(tBu)ester

    NOTA-bis(t-Butyl ester)

    		 Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Drug Derivative Cancer
    NOTA-bis (tBu) ester is a derivative of NOTA (HY-134418). NOTA-bis (tBu) ester is radiolabeled with 68Ga to form ZD2-( 68Ga-NOTA) after conjugation with ZD2. ZD2-( 68Ga-NOTA) can be used for PET imaging studies of pancreatic cancer .
    NOTA-bis(tBu)ester
  • HY-W003969
    Aminopicoline

    Ascensil; 2-Amino-4-methylpyridine

    		 NO Synthase Inflammation/Immunology
    Aminopicoline (Ascensil) is a potent and non-selective inhibitor of nitric oxide synthase (NOS) isoenzymes (iNOS, nNOS, eNOS). Aminopicoline competes with arginine at the substrate-binding site of nitric oxide synthase, reduces cellular nitric oxide production, inhibits the elevation of plasma nitrate, increases mean arterial pressure at high doses, and also serves as a basis for radiolabeled ligands to localize nitric oxide synthase binding sites. Aminopicoline can be used in the research of diseases associated with septic shock, joint inflammation, intestinal inflammation, and CNS inflammation .
    Aminopicoline
  • HY-157977
    DOTA-GA-maleimide

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) MMP Cancer
    DOTA-GA-maleimide is a bifunctional chelator with protein conjugation and radiometal chelation capabilities. DOTA-GA-maleimide forms stable complexes with 111In and conjugates with proteins via maleimide chemistry. DOTA-GA-maleimide conjugates with LFn, enabling 111In radiolabeling of LFn through direct or pre-labeling strategies. Radiolabeled LFn is applicable to MMP activity imaging studies. DOTA-GA-maleimide is used in cancer research .
    DOTA-GA-maleimide
  • HY-B0727
    Betamethasone valerate
    1 Publications Verification

    Betamethasone 17-valerate

    		 Glucocorticoid Receptor Inflammation/Immunology
    Betamethasone valerate (Betamethasone 17-valerate), the 17-valerate ester of Betamethasone, is a topical corticosteroid with anti-inflammatory activity. Betamethasone valerate is used in the treatment of recurrent aphthous stomatitis. Betamethasone valerate inhibits the binding of the radiolabeled glucocorticoid dexamethasone ( 3H dexamethasone) to human epidermis and mouse skin with IC50s of 5 and 6 nM, respectively .
    Betamethasone valerate
  • HY-75706
    N-Descyclopropanecarbaldehyde Olaparib

    		PARP Ligands for Target Protein for PROTAC Cancer
    N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 (HY-141481) . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .
    N-Descyclopropanecarbaldehyde Olaparib
  • HY-W342664
    2'-Deoxy-2'-fluoro-5-iodouridine

    FIRU

    		 Nucleoside Antimetabolite/Analog HSV Cancer
    2'-Deoxy-2'-fluoro-5-iodouridine (FIRU) is a nucleoside analog. When labeled with 123I, 2'-Deoxy-2'-fluoro-5-iodouridine accumulates highly selectively in tumors expressing the HSV1-tk gene. Radiolabeled 2'-Deoxy-2'-fluoro-5-iodouridine enables imaging of adenovirus-mediated HSV1-tk suicide gene transfer .
    2'-Deoxy-2'-fluoro-5-iodouridine
  • HY-101178
    L-689560

    		iGluR Neurological Disease
    L-689560 is a potent N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site. L-689560 is widely used as a radiolabeled ligand in binding studies and used for study the roles of NMDA receptors in normal neurological processes as well as in diseases .
    L-689560
  • HY-P10137
    Satoreotide

    JR11

    		 Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing .
    Satoreotide
  • HY-P3440
    WL12

    		Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1 Cancer
    WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .
    WL12
  • HY-149766
    PB94

    		HDAC Neurological Disease
    PB94 is a selective HDAC11 inhibitor (IC50=108 nM). PB94 can be radiolabeled as [11C]-PB94 for use in positron emission tomography (PET), as well as brain uptake and metabolic properties in administered live animals. PB94 improves neuropathic pain in mice and could be used to study neurological indications .
    PB94
  • HY-175023
    OncoACP3

    		Phosphatase Cancer
    OncoACP3 is a small-molecule ligand of prostatic acid phosphatase (ACP3) with an IC50 of 0.30 nM. OncoACP3 has a modular structure that supports flexible payload delivery. After radiolabeling with Lu-177 it selectively accumulates in ACP3-expressing tumors with a long retention time, enabling targeted radiation delivery. OncoACP3 is applicable to research related to prostate cancer .
    OncoACP3
  • HY-P5018
    NOTA-AE105

    		Radionuclide-Drug Conjugates (RDCs) Ser/Thr Protease Cancer
    NOTA-AE105 is a PET ligand for the urokinase-type plasminogen activator receptor (uPAR). NOTA-AE105 can be radiolabeled with 64Cu and 68Ga. Images of 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 demonstrate high contrast and clear tumor delineation. NOTA-AE105 can be used in the synthesis of radionuclide-conjugated compounds (RDCs) .
    NOTA-AE105
  • HY-158067
    Deferoxamine-DBCO

    DFO-DBCO

    		 Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as 89Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .
    Deferoxamine-DBCO
  • HY-W539893
    NODAGA-tris(t-Bu ester)

    NODAG

    		 Biochemical Assay Reagents Cancer
    NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .
    NODAGA-tris(t-Bu ester)
  • HY-101183
    THK5351

    		Tau Protein Neurological Disease
    THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.
    THK5351
  • HY-131009
    Fluorescein-NAD+

    		PARP Others
    Fluorescein-NAD+ is an alternative to radiolabeled NAD and a substrate for ADP-ribosylation. Fluorescein-NAD+ can be used in PARP assays by fluorescence microscopy. Extinction Coefficient: 262 nm.
    Fluorescein-NAD+
  • HY-164574
    BCN-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-DOTA is a cyclooctyne-linked DOTA chelator that can be radiolabeled with zirconium-89 as a radionuclide-labeled drug conjugate (RDC) to target specific biomolecules, cells, or tissues.
    BCN-DOTA
  • HY-153551
    HBED-CC-tris(tert-butyl ester)

    		Biochemical Assay Reagents Cancer
    HBED-CC-tris(tert-butyl ester) is a derivative of HBED-CC and a bifunctional chelator. HBED-CC-tris(tert-butyl ester) can be used in the research of radiolabeling and compounds for tumor-assisted diagnosis .
    HBED-CC-tris(tert-butyl ester)
  • HY-P10239
    Tyr3-Octreotate

    		Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs) Cancer
    Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [ 111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [ 90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .
    Tyr3-Octreotate
  • HY-B1684
    Mebrofenin

    SQ 26962

    		 Biochemical Assay Reagents Others
    Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function .
    Mebrofenin
  • HY-159768A
    DOTAGA.Glu.(FAPi)2

    		Radionuclide-Drug Conjugates (RDCs) FAP Neurological Disease Cancer
    DOTAGA.Glu.(FAPi) 2 is a FAPI homodimer in which a central glutamic acid (Glu) linker connects FAPI and a chelator. Radiolabeled with gallium- 68, lutetium- 177 or terbium- 161, DOTAGA.Glu.(FAPi) 2 is applicable to FAP-positive cancer PET imaging studies. DOTAGA.Glu.(FAPi) 2 is suitable for research related to prostate adenocarcinoma and recurrent glioblastoma multiforme .
    DOTAGA.Glu.(FAPi)2
  • HY-15404
    Darusentan

    Lu-135252

    		 Endothelin Receptor Cardiovascular Disease Endocrinology
    Darusentan (Lu-135252) is a selective endothelin receptor A (ET-A) receptor antagonist, which binds with a Ki of 1.4 nM to the ET-A receptor and a Ki of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors . Darusentan competes for radiolabeled endothelin binding in rat aortic vascular smooth muscle cells (RAVSMs) membranes with single-site kinetics, exhibiting a Ki of 13 nM .
    Darusentan
  • HY-P10896
    NOTA-P2-RM26

    		Bombesin Receptor Cancer
    NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
    NOTA-P2-RM26
  • HY-136201
    Sodium Glucoheptonate

    		Biochemical Assay Reagents Cancer
    Sodium Glucoheptonate is used as a kit for radio-labeling with Tc-99m. Tc-99m glucoheptonate is kidney- and brain-imaging agent, and can be used in brain-tumor detection .
    Sodium Glucoheptonate
  • HY-128710
    2'-Fluorothymidine

    2'-​Deoxy-​2'-​fluoro-​5-​Methyluridine

    		 Nucleoside Antimetabolite/Analog Cancer
    2'-Fluorothymidine (2'-Fluoro-2'-deoxythymidine) is a nucleoside analog and hCNT inhibitor, with an IC50 of 1.1 μM against hCNT1 and an IC50 of 9.7 μM against hCNT3. 2'-Fluorothymidine undergoes phosphorylation by cytosolic thymidine kinase (TK1) and mitochondrial thymidine kinase (TK2). 2'-Fluorothymidine acts as a backbone stabilizer in oligonucleotide synthesis and can also form radiolabeled candidates. 2'-Fluorothymidine is applicable in tumor-related research .
    2'-Fluorothymidine
  • HY-76573
    ML-10

    		Apoptosis Cardiovascular Disease Cancer
    ML-10 is a small molecule apoptosis probe. Due to the presence of fluorine atoms, ML-10 can be radiolabeled with 18F isotopes and can be used for apoptosis positron emission tomography imaging studies. ML-10 is selectively taken up and accumulated in apoptotic cells, while being excluded from live or necrotic cells. In addition, the uptake of ML-10 is associated with apoptotic features such as caspase activation, Annexin-V binding, and disruption of mitochondrial membrane potential .
    ML-10
  • HY-P11451
    Pentixather

    		CXCR Cancer
    Pentixather is a radiolabeled peptide that can target CXCR4. Pentixather can disrupt the interaction between leukemic cells and the bone marrow microenvironment by targeting the CXCR4/CXCL12 signaling axis, reduce the retention of leukemic cells in the protective bone marrow niche, and thereby enhance the sensitivity of leukemic cells to treatment. Pentixather can be used for the study of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .
    Pentixather
  • HY-137391
    2-Bromoestradiol

    		Estrogen Receptor/ERR Metabolic Disease
    2-Bromoestradiol is a estrogen 2-hydroxylase inhibitor. 2-Bromoestradiol decreases irreversible binding of radiolabeled estradiol metabolite(s) to microsomal proteins .
    2-Bromoestradiol
  • HY-147385
    CCR4 antagonist 3

    		CCR Inflammation/Immunology
    CCR4 antagonist 3 is a potent chemokine receptor 4 (CCR4) antagonist with an IC50 value of 1.7 μM for [ 125I]TARC (thymus and activation regulated chemokine). CCR4 antagonist 3 inhibits binding of radiolabeled TARC and macrophage-derived chemokine (MDC) to CCR4 receptors on the surface of CEM cells. CCR4 antagonist 3 also inhibits the in vitro migration of CEM cells mediated by TARC (IC50 = 6.4 μM) .
    CCR4 antagonist 3
  • HY-P10781
    PSMA-D5

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    PSMA-D5 has a binding affinity for PSMA with a Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    PSMA-D5
  • HY-N6793
    Phomopsin A

    		Microtubule/Tubulin Cancer
    Phomopsin A is a cyclic hexapeptide mycotoxin isolated from the fungus Phomopsis leptostomiformis. Phomopsin A is a noncompetitive inhibitor of the binding of radiolabeled vincristine to tubulin .
    Phomopsin A
  • HY-118852
    Isoxaben

    		Herbicide Others
    Isoxaben, a herbicide, inhibits incorporation of radiolabeled glucose into an acid insoluble cell wall fraction. Isoxaben is also a specific inhibitor of cell wall biosynthesis .
    Isoxaben
  • HY-153551A
    HBED-CC-tris(tert-butyl ester) TFA

    		Biochemical Assay Reagents Others
    HBED-CC-tris(tert-butyl ester) TFA is a derivative of HBED-CC and a bifunctional chelator. HBED-CC-tris(tert-butyl ester) TFA can be used in the research of radiolabeling and compounds for tumor-assisted diagnosis .
    HBED-CC-tris(tert-butyl ester) TFA
  • HY-P4681
    (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat)

    		Melanocortin Receptor Metabolic Disease
    (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) is a fragment of the ACTH hormone. (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) can be labeled with I125 on Tyr23 to produce a radiolabeled ligand .
    (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat)
  • HY-P10444
    DOTA Conjugated JM#21 derivative 7

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA Conjugated JM#21 derivative 7
  • HY-169868
    NOTA-FAPI-52

    		Biochemical Assay Reagents Cancer
    NOTA-FAPI-52 is a tracer with potent tumor uptake. NOTA-FAPI-52 can be radiolabeled to enable PET imaging or other bioimaging techniques. NOTA-FAPI-52 can be used to study diseases in which fibroblast activation protein (FAP) is overexpressed .
    NOTA-FAPI-52
  • HY-W097054
    Fmoc-L-cysteic acid

    		Amino Acid Derivatives Others
    Fmoc-L-cysteic acid is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize triarylsulfonium compounds for radiolabeling of peptides .
    Fmoc-L-cysteic acid
  • HY-131009A
    Fluorescein-NAD+ sodium

    		PARP Others
    Fluorescein-NAD+ sodium is an alternative to radiolabeled NAD and a substrate for ADP-ribosylation. Fluorescein-NAD+ sodium can be used in PARP assays by fluorescence microscopy. Extinction Coefficient: 262 nm.
    Fluorescein-NAD+ sodium
  • HY-P11254
    DOTA-FAPT

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-FAPT is a novel targeting FAP tracer. DOTA-FAPT can be radiolabeled with gallium-68 and lutetium-177. DOTA-FAPT can be used for PET imaging studies of cancer-associated fibroblasts .
    DOTA-FAPT
  • HY-162343
    PD-1/PD-L1-IN-41

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and PD-1 inhibitor with IC50 value of 10.2 nM .
    PD-1/PD-L1-IN-41
  • HY-P11257
    DOTA-BP1

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [ 68Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma .
    DOTA-BP1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: